We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Barr, Teva Resolve Sepracor Litigation Over Generic Xopenex
Barr, Teva Resolve Sepracor Litigation Over Generic Xopenex
March 17, 2009
Sepracor will allow Teva Pharmaceuticals USA and its Barr Laboratories subsidiary to market generic versions of Sepracor’s inhaled respiratory drug Xopenex as part of a settlement of a patent infringement lawsuit.